Replies to post #421430 on NorthWest Biotherapeutics Inc (NWBO)

[Jack2479]

Well the rules for the specials program won’t change until the NHS agrees to fund it to everyone on an equitable basis in the UK. The only thing changing in the short term is that Advent can scale the capacity up to around 40/50 per month from the specials program. Approval and pricing is agreed between the NHS and NWBO on a scale based around safety, efficacy and improvement to life and also using existing treatments costs as a benchmark. The more benefit the higher the price etc

[Jack2479]

I don’t have any expectations of anything like $100m in revenue for NWBO directly but in total yes the revenue will be slightly north of $100m - Advent will be a significant recipient of this revenue as they don’t own the vaccine but are a third party contract manufacturer and can charge what they like.

Without commercial scale as a personalised vaccine DCVax won’t get approval so Advent being scaled up has a benefit to shareholders of NWBO but will in its own right become an extremely valuable entity…